Ashwagandha and Pregnancy: Why It's Not Recommended

Ashwagandha and Pregnancy is a question that comes up frequently in supplement forums and prenatal clinics. The herb has built a strong reputation for stress relief and hormonal balance in non-pregnant adults, which naturally leads expecting mothers to wonder if it is safe for them too. The short answer, based on the current evidence, is no — ashwagandha is not recommended during pregnancy, and the reasons range from gaps in human safety data to plausible biological mechanisms that could pose risk.

What the Evidence Actually Shows

The clinical literature on ashwagandha is robust for general adult populations, but it is almost entirely silent on pregnancy. The five key human trials provided for this review — Chandrasekhar et al. (2012), Langade et al. (2019), Wankhede et al. (2015), Choudhary et al. (2017), and Pratte et al. (2014) — all excluded pregnant participants by design. These were randomized controlled trials (RCTs) and a systematic review focused on stress, anxiety, sleep, muscle strength, and cognitive function in otherwise healthy adults.

Chandrasekhar et al. (2012) randomized 64 adults with chronic stress to 300 mg of full-spectrum ashwagandha root extract or placebo for 60 days. The treatment group showed significant reductions in serum cortisol and stress-assessment scores. Langade et al. (2019) studied 60 adults with insomnia and anxiety using 300 mg of ashwagandha root extract twice daily for 10 weeks, reporting improvements in sleep onset latency and sleep efficiency. Wankhede et al. (2015) examined muscle strength and recovery in 57 healthy young men taking 300 mg twice daily for eight weeks. Choudhary et al. (2017) enrolled 50 adults to assess memory and cognitive function with 300 mg twice daily. Pratte et al. (2014) conducted a systematic review of human trials for ashwagandha in anxiety, concluding that the evidence is promising but limited by small sample sizes and methodological variability.

None of these studies enrolled pregnant women. None tested fetal outcomes, placental transfer, or teratogenicity. This is not a minor omission — it is the central issue. In pharmacology, absence of evidence in a vulnerable population is treated as evidence of absence of safety, not absence of risk.

<

Study	Population	Dose & Duration	Outcome	Pregnancy Data
Chandrasekhar et al. (2012)	64 adults with chronic stress	300 mg/day, 60 days	Reduced cortisol and stress scores	Excluded
Langade et al. (2019)	60 adults with insomnia	600 mg/day, 10 weeks	Improved sleep efficiency	Excluded
Wankhede et al. (2015)	57 healthy young men	600 mg/day, 8 weeks	Increased muscle strength	Excluded
Choudhary et al. (2017)	50 adults	600 mg/day, 8 weeks	Improved memory and cognitive function	Excluded
Pratte et al. (2014)	Systematic review of human trials	Variable	Promising but limited evidence for anxiety	No pregnancy trials included

Why the Mechanism Matters

Ashwagandha (Withania somnifera) is classified as an adaptogen, but its pharmacology is more specific than that label suggests. The primary bioactive compounds, withanolides, interact with the hypothalamic-pituitary-adrenal (HPA) axis, GABA receptors, and inflammatory signaling pathways. These are not neutral targets during pregnancy.

During gestation, the maternal HPA axis is already under profound natural regulation. Placental corticotropin-releasing hormone (CRH) rises exponentially, and maternal cortisol levels increase two- to four-fold by the third trimester. This is not a bug — it is a feature. Elevated cortisol helps mature fetal lungs and prepare the placenta for delivery. Introducing an exogenous compound that modulates cortisol synthesis or receptor sensitivity could theoretically disrupt this tightly choreographed endocrine environment. Chandrasekhar et al. (2012) demonstrated that ashwagandha lowers cortisol in stressed adults. In pregnancy, that same effect could be maladaptive.

Withanolides also exhibit GABA-mimetic activity. GABA is the main inhibitory neurotransmitter in the adult brain, but its role in fetal neurodevelopment is complex and stage-dependent. Early in gestation, GABA acts as an excitatory signal in the developing brain before the chloride gradient shifts. Exogenous modulation of GABAergic signaling during this window has been associated with developmental concerns in other drug classes, though direct evidence for ashwagandha specifically does not exist.

Additionally, ashwagandha has demonstrated uterine stimulant effects in animal models. While these studies are not provided in the reference list and should not be overstated, they are widely cited in pharmacology databases and have led to the herb's traditional contraindication in pregnancy across Ayurvedic and Western herbal medicine. The mechanism is thought to involve prostaglandin modulation and smooth muscle contractility, but human data is limited.

What the Guidelines Say

Major medical and regulatory bodies align on this point. The American College of Obstetricians and Gynecologists (ACOG) does not list ashwagandha as a recommended supplement during pregnancy. The Natural Medicines Database, a widely used clinical reference, rates ashwagandha as "Likely Unsafe" in pregnancy due to the lack of human safety data and the animal findings mentioned above. The European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have not approved ashwagandha for any indication, including pregnancy.

It is worth distinguishing between "no evidence of harm" and "evidence of no harm." The former describes ashwagandha in pregnancy. The clinical trials in non-pregnant adults showed generally favorable safety profiles at doses of 300–600 mg per day, with mild gastrointestinal upset being the most common adverse event. Langade et al. (2019) reported no serious adverse events over 10 weeks. Wankhede et al. (2015) noted no clinically significant changes in liver or kidney markers. But these findings do not extrapolate to pregnancy. Physiological changes in drug metabolism — increased plasma volume, altered hepatic enzyme expression, and placental transfer — mean that a compound safe in healthy adults is not automatically safe in pregnant women.

When Ashwagandha Makes Sense — and When It Doesn't

For non-pregnant adults with chronic stress, anxiety, or sleep disruption, the evidence is genuinely encouraging. Chandrasekhar et al. (2012) and Langade et al. (2019) provide RCT-level support for cortisol reduction and sleep improvement. Choudhary et al. (2017) adds cognitive function to the list. For women who are trying to conceive, some evidence (not included in the provided references) suggests ashwagandha may support hormonal balance and reduce stress-related fertility barriers. Our article on Ashwagandha and Fertility: Evidence for Male and Female Reproductive Health covers this in more detail.

However, the transition from preconception to confirmed pregnancy is the point at which ashwagandha should be discontinued. This is not a subtle nuance — it is a hard stop. The same properties that make ashwagandha appealing for stress and hormonal regulation — HPA axis modulation, GABAergic activity, and potential uterine effects — become liabilities when a developing embryo or fetus is involved. For women who have been using ashwagandha as part of a preconception routine, stopping once pregnancy is confirmed is the conservative and evidence-aligned choice.

For those considering ashwagandha postpartum, the situation is different but still requires caution. Lactation safety data is also sparse. The general principle remains: if a compound crosses biological membranes and modulates endocrine or neurotransmitter systems, it should not be assumed safe for a breastfeeding infant without direct evidence.

Who Benefits Most From Ashwagandha

The evidence is strongest for non-pregnant adults with specific, identifiable complaints. Based on the provided references:

• Chronically stressed adults: Chandrasekhar et al. (2012) showed meaningful cortisol reduction and improved stress-assessment scores in adults with chronic stress. This is the most robust indication in the provided literature.
• Adults with insomnia and anxiety: Langade et al. (2019) demonstrated improved sleep efficiency and reduced anxiety scores over 10 weeks. The effect size was modest but statistically significant.
• Athletes seeking strength and recovery: Wankhede et al. (2015) reported increased muscle strength and reduced exercise-induced muscle damage in young men. This population is clearly non-pregnant and male, which sidesteps the pregnancy question entirely.
• Adults with mild cognitive concerns: Choudhary et al. (2017) found improvements in memory, executive function, and sustained attention. Again, this study excluded pregnant participants.

For women specifically, ashwagandha's benefits for stress and hormonal balance are well-documented in non-pregnant populations. Our article on Ashwagandha for Women: Hormonal Balance, Stress and Libido Evidence explores this in depth. The key is timing: preconception and postpartum (with medical guidance) are different risk-benefit contexts than active pregnancy.

Practical Takeaways

• Do not take ashwagandha during pregnancy. No human safety data exists, and the biological mechanisms raise plausible concerns.
• Stop ashwagandha once pregnancy is confirmed, even if you were taking it preconception. The risk-benefit calculus changes immediately.
• Discuss any supplement use with your obstetrician. This includes "natural" or "Ayurvedic" products. The source of a compound does not determine its safety profile.
• Be cautious with ashwagandha while breastfeeding. Lactation safety data is also insufficient. If stress management is needed postpartum, behavioral interventions and approved medications should be considered first.
• Choose third-party tested products when appropriate. For non-pregnant adults, quality matters. Products like Bio:sudo KSM-66 Reishi Restore use standardized extracts with defined withanolide content, which is preferable to unstandardized raw powders. This is irrelevant during pregnancy, but relevant for preconception or postpartum use with medical approval.
• Read labels carefully. Ashwagandha is increasingly added to "stress-relief" blends, sleep aids, and even protein powders. Pregnant women should scan ingredient lists for Withania somnifera and related extracts.

What About Side Effects in General?

For non-pregnant adults, ashwagandha's side effect profile is relatively benign. Pratte et al. (2014) noted in their systematic review that adverse events were generally mild and transient. The most commonly reported issues were gastrointestinal discomfort, drowsiness, and headache. No serious adverse events were reported across the trials included in their analysis. However, the review also flagged the limitations: small sample sizes, short durations, and heterogeneous extract formulations.

For a deeper look at the safety data, including rare case reports and drug interactions, see our article on Ashwagandha Side Effects: What the Clinical Evidence and Case Reports Show. The key point for pregnancy is that "mild side effects in healthy adults" is a very different standard than "safe for fetal development."

Bottom Line

Ashwagandha has a legitimate evidence base for stress, anxiety, sleep, and cognitive function in non-pregnant adults. Chandrasekhar et al. (2012), Langade et al. (2019), and the other provided references support its use in those populations. But pregnancy is a different biological state with different risk thresholds. No human trials have tested ashwagandha in pregnant women, and the herb's mechanisms — HPA axis modulation, GABAergic activity, and potential uterine effects — provide biologically plausible reasons for caution. The consensus among medical authorities is clear: avoid ashwagandha during pregnancy and use it in other life stages only with appropriate medical guidance.

References

1. Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." Indian Journal of Psychological Medicine. 2012;34(3):255–262. [Source]
2. Langade D, et al. "Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety." Medicine. 2019;98(37):e17186. [Source]
3. Wankhede S, et al. "Examining the effect of Withania somnifera supplementation on muscle strength and recovery." Journal of the International Society of Sports Nutrition. 2015;12:43. [Source]
4. Choudhary D, et al. "Efficacy and safety of ashwagandha (Withania somnifera) root extract in improving memory and cognitive functions." Journal of Dietary Supplements. 2017;14(6):599–612. [Source]
5. Pratte MA, et al. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha." Journal of Alternative and Complementary Medicine. 2014;20(12):901–908. [Source]

---

---